Publications by authors named "P M Venner"
Article Synopsis
- High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is a standard treatment for patients with metastatic germ cell tumors (mGCTs) who relapse after conventional chemo, and this study reviews its effectiveness in Alberta, Canada, over 20 years.
- A review of 43 patients treated with HDC-ASCT revealed a median age of 28, with most having non-seminoma tumors; survival rates showed 42% were disease-free at last follow-up.
- The findings suggest that HDC-ASCT is an effective second-line therapy for mGCT, with indications that tandem transplants may yield better outcomes, though the results are limited by a small sample size.
Purpose: The Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository was established in 2014 by the APCaRI to facilitate the collection of clinical and patient-reported data, biospecimen, to measure prostate cancer outcomes and to support the development and clinical translation of innovative technologies to better diagnose and predict outcomes for patients with prostate cancer.
Participants: Men suspected with prostate cancer and referred to Urology centres in Alberta were enrolled in the APCaRI 01 study, while men with a prior prostate cancer diagnosis participated in the APCaRI 03 study from 1 July 2014 to 30 June 2019. The APCaRI Registry and Biorepository links biospecimens and data from a wide representation of patients drawn from an Alberta population of more than 4 million.
Introduction: Enzalutamide (Enza) is an effective treatment for metastatic castrate-resistant prostate cancer (mCPRC). However, Enza is not cost-effective (CE) at willingness to pay (WTP) thresholds from $0-$125 000/quality adjusted life years (QALYs) and is therefore a strain on valuable health care dollars. Metformin (Met) is inexpensive (~$8.
View Article and Find Full Text PDFBackground: Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.
Materials And Methods: In a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days.